One of the busy phone rings on the desk of Scripps Tech Transfer Office?
On July 15, 2010 Allozyne Inc. announced the signing of a worldwide licensing agreement with The Scripps Research Institute. It provides Allozyne with a license to apply click chemistry for exclusive development in key therapeutic fields in addition to a non-exclusive license for diagnostic applications. Allozyne’s biociphering platforms, CAESAR and VIGENÈRE, enable the site-specific incorporation of these “Click” components into virtually any protein and thereby provide a unique site at which any number of payloads can be securely attached - polymers, small molecules, antibodies, toxins, additional proteins and peptides - for building therapeutics not previously possible.
Notably, among the Scientific Advisory Board of Allozyne, are Barry Sharpless and David A. Tirrell, both of whom are listed in this blog's Click Chemistry Links.